{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:59:53Z","timestamp":1792407593943,"version":"4.4.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":146,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n With increased use of immune checkpoint inhibitors (ICIs) among patients with cancer, there is substantial interest in understanding clinical and economic outcomes and management of immune-related adverse events (irAEs).<\/jats:p>\n <\/jats:sec>\n \n Patients, Materials, and Methods<\/jats:title>\n A retrospective study was conducted using Premier Healthcare Database, a U.S. national hospital discharge database, from March 1, 2015, through December 31, 2017. The database comprises more than 880 million inpatient and hospital-based outpatient encounters, with more than 200 million unique patients reported by 966 hospitals. Patients with four solid tumors known to benefit from ICI therapy were included. The list of irAEs assessed was defined a priori per American Society of Clinical Oncology clinical guidelines for irAE management. Baseline irAE-related inpatient and outpatient visits were defined as the first inpatient or hospital-based outpatient visit with discharge diagnosis of any irAE of interest following confirmed ICI usage within 90\u2009days prior to the baseline visit. Patients were followed for 90\u2009days after baseline irAE-related inpatient discharge date or outpatient visit date to assess irAE-related inpatient admissions, all-cause in-hospital mortality, ICI reinitiation, and to determine costs and health care resource utilization.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Records from 673,957 patients with four tumor types were reviewed for ICI therapy. Of 13,030 patients receiving ICIs, approximately 40% experienced at least one irAE, with a total of 10,121 irAEs occurring within 90\u2009days of the ICI visit. The most frequent (&gt;1,000 events) irAEs were anemia, impaired ventricular function with heart failure and vasculitis, thrombocytopenia, thyroid conditions, and peripheral edema. As might be expected, compared with those with baseline irAE-related outpatient visits, patients with baseline irAE-related inpatient visits had a significantly higher percentage of irAE-related inpatient admissions (23% vs. 14%) and all-cause in-hospital mortality (22% vs. 6%) and lower reinitiation of ICI therapy (31% vs. 71%). Baseline irAE-related inpatient visits had significantly higher mean costs ($29,477 vs. $5,718) with longer hospital stays (12.6 vs. 7.8\u2009days).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Findings from a U.S. national hospital discharge database suggest that irAEs in patients treated with ICIs are common, occur in multiples and with greater frequency in those with pre-existing comorbidities. Those with inpatient admissions have poorer outcomes.<\/jats:p>\n <\/jats:sec>\n \n Implications for Practice<\/jats:title>\n The present work addressed the knowledge gap in understanding real-world outcomes of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). Patients who experienced irAEs had significantly higher baseline comorbidities and were more likely to have immune-related or immune-compromised comorbid conditions. Patients with baseline irAE-related hospitalizations were more likely to be rehospitalized and to experience in-hospital mortality and less likely to reinitiate ICI treatment. Real-world patients are more diverse than clinical trials, and clinicians should consider both the efficacy and safety profile of ICI treatments, especially for patients with comorbidity conditions. Close monitoring is needed after patients have experienced an irAE.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/onco.13918","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T07:00:31Z","timestamp":1627628431000},"page":"e2002-e2012","source":"Crossref","is-referenced-by-count":49,"title":["Real-World<\/scp> Clinical and Economic Outcomes in Selected Immune-Related<\/scp> Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors"],"prefix":"10.1093","volume":"26","author":[{"given":"Ying","family":"Zheng","sequence":"first","affiliation":[{"name":"EMD Serono, Rockland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Kim","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yu","sequence":"additional","affiliation":[{"name":"EMD Serono, Rockland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Gayle","sequence":"additional","affiliation":[{"name":"Premier Applied Sciences \u00a0Premier Inc, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Wassel","sequence":"additional","affiliation":[{"name":"Premier Applied Sciences \u00a0Premier Inc, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Dreyfus","sequence":"additional","affiliation":[{"name":"Premier Applied Sciences \u00a0Premier Inc, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Phatak","sequence":"additional","affiliation":[{"name":"EMD Serono, Rockland, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saby","family":"George","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2022011714473265800_onco13918-bib-0001","first-page":"452","article-title":"Cancer immunotherapy, part 2: Efficacy, safety, and other clinical considerations","volume":"42","author":"Ventola","year":"2017","journal-title":"P T"},{"key":"2022011714473265800_onco13918-bib-0002","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2022011714473265800_onco13918-bib-0003","doi-asserted-by":"crossref","first-page":"14039","DOI":"10.1038\/s41598-019-50574-6","article-title":"Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab","volume":"9","author":"Eun","year":"2019","journal-title":"Sci Rep"},{"key":"2022011714473265800_onco13918-bib-0004","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.annonc.2019.10.008","article-title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: A systematic review and meta-analysis of randomized clinical trials","volume":"31","author":"Magee","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2022011714473265800_onco13918-bib-0005","article-title":"Health care utilization associated with adverse events (AEs) among metastatic non-small cell lung cancer (mNSCLC) patients treated with immunotherapy or chemotherapy","volume":"37","author":"Engel-Nitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022011714473265800_onco13918-bib-0006","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: A preplanned interim analysis of a clinical trial","volume":"4","author":"D'Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"2022011714473265800_onco13918-bib-0007","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2022011714473265800_onco13918-bib-0008","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000200","article-title":"Immune checkpoint inhibitors for advanced non-small cell lung cancer: Emerging sequencing for new treatment targets","volume":"2","author":"Aguiar","year":"2017","journal-title":"ESMO Open"},{"key":"2022011714473265800_onco13918-bib-0009","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: Experience to date and future directions","volume":"28","author":"Atkins","year":"2017","journal-title":"Ann Oncol"},{"key":"2022011714473265800_onco13918-bib-0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ctrv.2017.12.007","article-title":"Immune checkpoint inhibitors for metastatic bladder cancer","volume":"64","author":"Massari","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2022011714473265800_onco13918-bib-0011","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1634\/theoncologist.2019-0299","article-title":"Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer","volume":"25","author":"Akamatsu","year":"2020","journal-title":"The Oncologist"},{"key":"2022011714473265800_onco13918-bib-0012","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"2022011714473265800_onco13918-bib-0013","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022011714473265800_onco13918-bib-0014","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr Oncol"},{"key":"2022011714473265800_onco13918-bib-0015","article-title":"The financial and physical toxicity of immune checkpoint inhibitors in cancer","author":"Kelly","year":"2019","journal-title":"ASCO Daily News"},{"key":"2022011714473265800_onco13918-bib-0016","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2022011714473265800_onco13918-bib-0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2022011714473265800_onco13918-bib-0018","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022011714473265800_onco13918-bib-0019","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2022011714473265800_onco13918-bib-0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-related adverse events: A case-based approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"},{"key":"2022011714473265800_onco13918-bib-0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/L18-0209","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease","volume":"169","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"2022011714473265800_onco13918-bib-0022","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/phar.1643","article-title":"Immune checkpoint inhibitors: New insights and current place in cancer therapy","volume":"35","author":"La-Beck","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2022011714473265800_onco13918-bib-0023","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"2022011714473265800_onco13918-bib-0024","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2022011714473265800_onco13918-bib-0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14737140.2018.1499468","article-title":"Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: A critical review","volume":"18","author":"Babey","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"2022011714473265800_onco13918-bib-0026","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.cllc.2018.08.008","article-title":"Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer","volume":"19","author":"Owen","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2022011714473265800_onco13918-bib-0027","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00280-019-03926-y","article-title":"Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer","volume":"84","author":"Mouri","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022011714473265800_onco13918-bib-0028","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"2022011714473265800_onco13918-bib-0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000144","article-title":"Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma","volume":"8","author":"Abou Alaiwi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2022011714473265800_onco13918-bib-0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2147\/CEOR.S138963","article-title":"Cost analysis of adverse events associated with non-small cell lung cancer management in France","volume":"9","author":"Chouaid","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"2022011714473265800_onco13918-bib-0031","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s40261-018-0690-9","article-title":"Cost estimate of immune-related adverse reactions associated with innovative treatments of metastatic melanoma","volume":"38","author":"Mennini","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2022011714473265800_onco13918-bib-0032","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"2022011714473265800_onco13918-bib-0033","first-page":"Abstract 475","article-title":"Immune-related adverse events (irAEs) with single agent PD-1 vs PD-L1 inhibitors: A meta-analysis of 8,730 patients from clinical trials","volume":"30","author":"Sonpavde","year":"2019","journal-title":"Ann Oncol"},{"key":"2022011714473265800_onco13918-bib-0034","doi-asserted-by":"crossref","first-page":"Abstract 38","DOI":"10.1186\/s40425-017-0241-6","article-title":"The value of cancer immunotherapy summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary annual meeting","volume":"5","author":"Kaufman","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2022011714473265800_onco13918-bib-0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s40425-018-0442-7","article-title":"A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors","volume":"6","author":"Verma","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2022011714473265800_onco13918-bib-0036","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: Opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13918","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2002\/42204062\/oncolo_26_11_e2002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/11\/e2002\/42204062\/oncolo_26_11_e2002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T14:48:57Z","timestamp":1642430937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/11\/e2002\/6508795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13918","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,24]]}}}